[{"id":"28b013d0-bb25-4305-8b9d-0fa3589a3976","acronym":"","url":"https://clinicaltrials.gov/study/NCT01339650","created_at":"2021-01-18T05:28:01.185Z","updated_at":"2024-07-02T16:37:15.149Z","phase":"Phase 1","brief_title":"Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT01339650","lead_sponsor":"AbbVie (prior sponsor, Abbott)","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABT-767"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 05/06/2011","start_date":" 05/06/2011","primary_txt":" Primary completion: 11/30/2017","primary_completion_date":" 11/30/2017","study_txt":" Completion: 11/30/2017","study_completion_date":" 11/30/2017","last_update_posted":"2018-01-02"}]